Drugs / Curcumin
Curcumin
also known as
diferuloylmethane · Liposomal Curcumin · Longvida · CUR · Curcumin C3 Complex · LipoCurc · BCM-95 curcumin · BEC · +19 more
Small molecule targets CXCL8, VDR via inhibition / activation
Trials 128 · started per year
today
5
5
2
2
3
6
6
5
5
7
7
7
5
8
6
10
9
4
6
5
9
5
1
20042005200620072008200920102011201220132014201520162017201820192020202120222023202420252026202720282029
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 012 trials · 1 missed | ||||||
| Phase 0 | NCT06653231 | Nov 2024 → Feb 2025 | periodontitis | Cairo University | Completed | No outcome recorded |
| Phase 0 | NCT05147376 | Feb 2022 → Aug 2023 | ulcerative stomatitis | Chulalongkorn University | Completed | Missed primary |
| Phase 0 | NCT04403568 | Oct 2021 → Dec 2022 | prostate cancer | The University of Texas Health Science Center at San Antonio | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 0 | NCT04590196 | Nov 2020 → Jun 2023 | dry age related macular degeneration | University of Illinois at Chicago | Completed | No outcome recorded |
| Phase 0 | NCT04421716 | Oct → Nov 2020 | — | The University of Texas Health Science Center at San Antonio | Completed | No outcome recorded |
| Phase 0 | NCT04355416 | Apr → May 2020 | chronic periodontitis | University of Baghdad | Unknown | No outcome recorded |
| Phase 0 | NCT03584724 | Dec 2018 → Aug 2020 | uveitis | Eye Pharma | Completed | No outcome recorded |
| Phase 0 | NCT03845322 | Dec 2018 → Feb 2020 | — | University of New Mexico | Withdrawn | No outcome recorded |
| Phase 0 | NCT02724202 | Feb 2018 → Jan 2020 | metastasis from malignant tumor of colon | Baylor Research Institute | Terminated | No outcome recorded |
| Phase 0 | NCT02554344 | Jun 2015 → Jul 2017 | cervical intraepithelial neoplasia grade 2/3 | Baylor Research Institute | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 0 | NCT01160302 | Jun 2010 → Jan 2016 | head and neck squamous cell carcinoma | Louisiana State University Health Sciences Center Shreveport | Completed | No outcome recorded |
| Phase 0 | NCT00752154 | Jan → Dec 2010 | rheumatoid arthritis | University of California, Los Angeles | Completed | No outcome recorded |
| Phase 120 trials | ||||||
| Phase 1 | NCT07456605 | Feb 2026 → Mar 2028 expected | plasma cell myeloma | University Health Network, Toronto | Recruiting | No outcome recorded |
| Phase 1 | NCT06626230 | Mar 2025 → Jul 2026 overdue | anal canal carcinoma in situ | Lisa Flowers | Recruiting | No outcome recorded |
| Phase 1 | NCT06359665 | Feb 2025 → Feb 2026 overdue | osteoarthritis, hand | Brent DeGeorge | Enrolling by invitation | No outcome recorded |
| Phase 1 | NCT06044142 | Mar → Dec 2023 | chemotherapy-induced oral mucositis, childhood malignant neoplasm | Riyadh Elm University | Completed | No outcome recorded |
| Phase 1 | NCT06029023 | Dec 2022 → Sep 2024 | exposure, dental pulp | Al-Azhar University | Completed | No outcome recorded |
| Phase 1 | NCT04972045 | Apr 2021 | — | The Affiliated Hospital of Qingdao University | Completed | No outcome recorded |
| Phase 1 | NCT03980509 | Jan 2020 → Mar 2022 | breast cancer | Medical University of South Carolina | Completed | No outcome recorded |
| Phase 1 | NCT02598726 | Mar 2016 → Sep 2018 | cancer, urinary bladder disorder | Mayo Clinic | Completed | No outcome recorded |
| Phase 1 | NCT02321293 | Aug 2015 → Aug 2016 | lung cancer | Lady Davis Institute | Unknown | No outcome recorded |
| Phase 1 | NCT02337192 | Jan → Jun 2014 | — | University of Sao Paulo | Completed | No outcome recorded |
| Phase 1 | NCT01859858 | Jun 2013 → Oct 2016 | colorectal cancer | UNC Lineberger Comprehensive Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT02152475 | May → Nov 2013 | — | University of Sao Paulo | Completed | No outcome recorded |
| Phase 1 | NCT01608139 | Nov 2012 → Nov 2022 | high grade malignant neoplasm | M.D. Anderson Cancer Center | Withdrawn | No outcome recorded |
| Phase 1 | NCT01201694 | Oct 2011 → Jan 2014 | high grade malignant neoplasm | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT01403545 | Aug 2011 → Aug 2012 | — | SignPath Pharma, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01344291 | Jul 2011 → Jul 2012 | prolactin-producing pituitary gland adenoma | Mashhad University of Medical Sciences | Unknown | No outcome recorded |
| Phase 1 | NCT01333917 | Nov 2010 → Oct 2011 | colorectal cancer | University of North Carolina, Chapel Hill | Completed | No outcome recorded |
| Phase 1 | NCT01035580 | Jan 2010 → Apr 2011 | dysplasia of cervix | Emory University | Completed | No outcome recorded |
| Phase 1 | NCT00889161 | May 2009 → Jun 2010 | Crohn disease, ulcerative colitis | Seattle Children's Hospital | Completed | No outcome recorded |
| Phase 1 | NCT00219882 | Apr 2005 → Jan 2006 | cystic fibrosis | Ramsey, Bonnie, MD | Completed | No outcome recorded |
| Phase 1/212 trials | ||||||
| Phase 1/2 | NCT06413238 | Jun → Dec 2024 | diabetes mellitus | Fateme Moshirenia | Unknown | No outcome recorded |
| Phase 1/2 | NCT05688488 | May 2023 → Dec 2025 overdue | congenital laryngeal web, glottis carcinoma, laryngostenosis, leukoplakia +2 | Eye & ENT Hospital of Fudan University | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05768919 | Mar 2023 → Feb 2026 overdue | glioblastoma | SignPath Pharma, Inc. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT02978339 | Jun 2017 → Nov 2018 | primary sclerosing cholangitis | John E. Eaton | Completed | No outcome recorded |
| Phase 1/2 | NCT02848417 | Apr 2016 → Aug 2019 | persian gulf syndrome | South Florida Veterans Affairs Foundation for Research and Education | Unknown | No outcome recorded |
| Phase 1/2 | NCT02300727 | Feb 2015 → Oct 2018 | mucositis | Amy Beres | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1/2 | NCT02104752 | Jul 2014 → May 2016 | schizophrenia | VA Greater Los Angeles Healthcare System | Completed | No outcome recorded |
| Phase 1/2 | NCT02138955 | Mar 2014 → Nov 2017 | — | SignPath Pharma, Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT01490996 | Feb 2012 → May 2017 | colorectal cancer, metastatic malignant neoplasm | University of Leicester | Completed | No outcome recorded |
| Phase 1/2 | NCT01543386 | Feb → Apr 2012 | — | University Hospital, Clermont-Ferrand | Completed | No outcome recorded |
| Phase 1/2 | NCT00247026 | Apr 2007 → ? | myelodysplastic syndrome | Hadassah Medical Organization | Withdrawn | No outcome recorded Stop: Business |
| Phase 1/2 | NCT00164749 | Oct 2004 → Jul 2006 | Alzheimer disease | Chinese University of Hong Kong | Completed | No outcome recorded |
| Phase 234 trials · 4 missed | ||||||
| Phase 2 | NCT04266275 | Apr 2027 → Oct 2028 expected | cervical intraepithelial neoplasia | Lisa Flowers | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06829186 | Mar → Sep 2025 overdue | — | University of Guadalajara | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06342830 | Jun 2024 → Sep 2025 | periapical periodontitis | Ain Shams University | Completed | No outcome recorded |
| Phase 2 | NCT05966441 | Aug → Dec 2023 | chemotherapy-induced neuropathy | Ain Shams University | Unknown | No outcome recorded |
| Phase 2 | NCT05714670 | Apr → Oct 2023 | lupus nephritis | Ain Shams University | Completed | No outcome recorded |
| Phase 2 | NCT05596214 | Aug 2022 → Sep 2024 | diverticulitis | Dr. Adi Lahat | Unknown | No outcome recorded |
| Phase 2 | NCT04731844 | Dec 2021 → Sep 2024 | monoclonal gammopathy of uncertain significance, prostate cancer, smoldering plasma cell myeloma | University of Rochester | Completed | No outcome recorded |
| Phase 2 | NCT04294836 | Dec 2021 → Jan 2023 | cervical carcinoma | Instituto Nacional de Cancerologia, Columbia | Withdrawn | No outcome recorded |
| Phase 2 | NCT04353310 | Sep → Nov 2021 | asthma | Loma Linda University | Withdrawn | No outcome recorded Stop: Business |
| Phase 2 | NCT04132648 | Nov 2020 → Nov 2021 | chronic kidney disease | University of Iowa | Withdrawn | No outcome recorded |
| Phase 2 | NCT04499963 | Aug 2020 → Aug 2022 | amyotrophic lateral sclerosis | Richard Bedlack, M.D., Ph.D. | Completed | Missed primary |
| Phase 2 | NCT05430087 | Mar 2020 → Jan 2022 | systemic lupus erythematosus | Saiful Anwar Hospital | Completed | No outcome recorded |
| Phase 2 | NCT03953261 | Sep 2019 → Apr 2022 | systemic lupus erythematosus | Loma Linda University | Terminated | No outcome recorded |
| Phase 2 | NCT03223883 | Jun 2018 → Jan 2023 | chronic kidney disease, cognitive disorder | Diana Jalal | Completed | No outcome recorded |
| Phase 2 | NCT02944578 | Nov 2017 → Oct 2018 | neoplasm | Lisa Flowers | Terminated | No outcome recorded |
| Phase 2 | NCT02782949 | Apr 2017 → Oct 2022 overdue | chronic atrophic gastritis, gastric carcinoma | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03150966 | Jun 2016 → Aug 2017 | multiple sclerosis | Tabriz University of Medical Sciences | Completed | No outcome recorded |
| Phase 2 | NCT02724618 | Mar 2016 → Apr 2017 | prostate cancer | Shahid Beheshti University of Medical Sciences | Unknown | No outcome recorded |
| Phase 2 | NCT02556632 | Oct 2015 → Sep 2016 | breast carcinoma in situ, radiodermatitis | Gary Morrow | Completed | Missed primary |
| Phase 2 | NCT02439385 | Aug 2015 → Aug 2019 | colorectal cancer | Gachon University Gil Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT01740323 | May 2015 → Jul 2018 | breast cancer | Andrew H Miller | Completed | No outcome recorded |
| Phase 2 | NCT02100423 | Oct 2014 → Apr 2018 | chronic lymphocytic leukemia/small lymphocytic lymphoma | Paolo Caimi, MD | Completed | No outcome recorded |
| Phase 2 | NCT02095717 | Mar 2014 → Apr 2018 | castration-resistant prostate carcinoma | Centre Jean Perrin | Terminated | No outcome recorded |
| Phase 2 | NCT01811381 | Jan 2014 → Mar 2020 | cognitive impairment with or without cerebellar ataxia | VA Office of Research and Development | Unknown | No outcome recorded |
| Phase 2 | NCT02645656 | Dec 2013 → Feb 2016 | oral submucous fibrosis | SVS Institute of Dental Sciences | Unknown | No outcome recorded |
| Phase 2 | NCT01928043 | Sep 2013 → Mar 2017 | bipolar disorder | Sunnybrook Health Sciences Centre | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT00969085 | Nov 2012 → Nov 2014 | primary cutaneous T-cell lymphoma | M.D. Anderson Cancer Center | Withdrawn | No outcome recorded |
| Phase 2 | NCT01514370 | Apr 2012 → Mar 2016 | multiple sclerosis | Merck KGaA, Darmstadt, Germany | Completed | Missed primary |
| Phase 2 | NCT04870060 | Oct 2010 → Jul 2015 | chemotherapy-induced oral mucositis | Tata Memorial Centre | Completed | No outcome recorded |
| Phase 2 | NCT00641147 | Oct 2010 → Nov 2016 | classic familial adenomatous polyposis | National Cancer Institute (NCI) | Completed | Missed primary |
| Phase 2 | NCT00365209 | Oct 2006 → Sep 2008 | nicotine dependence | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT00248053 | Nov 2005 → Jun 2008 | classic or attenuated familial adenomatous polyposis | Johns Hopkins University | Withdrawn | No outcome recorded |
| Phase 2 | NCT00094445 | Nov 2004 → Apr 2014 | adenocarcinoma, pancreatic neoplasm | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT00192842 | Jul 2004 → Nov 2007 | malignant pancreatic neoplasm | Rambam Health Care Campus | Completed | No outcome recorded |
| Phase 2/37 trials · 2 missed | ||||||
| Phase 2/3 | NCT07278128 | Jun 2024 → Jul 2025 | polycystic ovary syndrome | Fateme Moshirenia | Completed | No outcome recorded |
| Phase 2/3 | NCT06281353 | Aug 2022 → Sep 2023 | anogenital human papillomavirus infection | Indonesia University | Completed | No outcome recorded |
| Phase 2/3 | NCT06595355 | Oct 2021 → Sep 2025 overdue | diabetic macular edema, macular retinal edema | Isfahan University of Medical Sciences | Recruiting | No outcome recorded |
| Phase 2/3 | NCT03262363 | Aug 2018 → Feb 2019 | chronic kidney disease, type 2 diabetes mellitus | Unidad de Investigacion Medica en Enfermedades Renales | Unknown | No outcome recorded |
| Phase 2/3 | NCT03085680 | Aug 2017 → Oct 2019 | cognitive disorder | University of Florida | Completed | No outcome recorded |
| Phase 2/3 | NCT01225094 | Nov 2011 → Nov 2014 | abdominal aortic aneurysm, acute kidney injury | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Completed | Missed primary |
| Phase 2/3 | NCT01246973 | Feb 2011 → Nov 2014 | radiodermatitis | University of Rochester | Completed | Missed primary |
| Phase 312 trials · 2 met primary · 1 missed | ||||||
| Phase 3 | NCT06381076 | Feb → May 2025 | end stage renal failure | University of Florida | Completed | Met primary |
| Phase 3 | NCT06605911 | Jun → Aug 2023 | lichen planus, oral | Shaymaa Hussein Rafat Kotb | Completed | No outcome recorded |
| Phase 3 | NCT02277223 | Mar 2020 → Jul 2022 | ulcerative colitis | Schneider Children's Medical Center, Israel | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT03790605 | Sep 2019 → Sep 2020 | periodontitis | KLE Society's Institute of Dental Sciences | Unknown | No outcome recorded |
| Phase 3 | NCT04896164 | Dec 2018 → May 2025 | chemotherapy-induced oral mucositis | Tata Memorial Centre | Unknown | No outcome recorded |
| Phase 3 | NCT04837664 | Jul 2018 → Dec 2020 | candidiasis | King Saud University | Unknown | No outcome recorded |
| Phase 3 | NCT02683759 | Feb 2016 → Feb 2017 | ulcerative colitis | Asian Institute of Gastroenterology, India | Unknown | No outcome recorded |
| Phase 3 | NCT02683733 | Feb 2016 → Feb 2017 | ulcerative colitis | Asian Institute of Gastroenterology, India | Unknown | No outcome recorded |
| Phase 3 | NCT02255370 | Dec 2014 → Nov 2017 | Crohn disease | University Hospital, Clermont-Ferrand | Completed | Missed primary |
| Phase 3 | NCT01320436 | Jul 2011 → Sep 2014 | ulcerative colitis | Sheba Medical Center | Completed | Met primary |
| Phase 3 | NCT00295035 | Mar 2006 → Mar 2007 | colonic neoplasm | Tel-Aviv Sourasky Medical Center | Unknown | No outcome recorded |
| Phase 3 | NCT00486460 | Jun 2005 → ? | pancreatic adenocarcinoma | Tel-Aviv Sourasky Medical Center | Unknown | No outcome recorded |
| Phase 411 trials · 1 met primary · 2 missed | ||||||
| Phase 4 | NCT07665294 | Oct 2026 → Jun 2027 expected | ulcerative colitis | Ryan C Ungaro | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07596927 | Jan 2026 overdue | acquired epidermolysis bullosa, epidermolysis bullosa dystrophica | Universidade Ceuma | Active not recruiting | No outcome recorded |
| Phase 4 | NCT06886035 | Mar → Dec 2025 | — | Erzincan Military Hospital | Completed | No outcome recorded |
| Phase 4 | NCT04971382 | Dec 2021 → Mar 2024 | periodontal disorder | Ain Shams University | Unknown | No outcome recorded |
| Phase 4 | NCT04528212 | Nov 2020 → Nov 2021 | type 2 diabetes mellitus | Rehab Werida | Completed | No outcome recorded |
| Phase 4 | NCT04205929 | Apr 2020 → Nov 2022 | hemorrhagic disease | Oregon Health and Science University | Completed | Missed primary |
| Phase 4 | NCT03917784 | Feb → Nov 2019 | prediabetes syndrome | Hospital General de México Dr. Eduardo Liceaga | Unknown | No outcome recorded |
| Phase 4 | NCT04032132 | Aug 2016 → May 2018 | periodontitis | Ain Shams University | Completed | No outcome recorded |
| Phase 4 | NCT02494141 | Nov 2015 → Feb 2021 | autosomal dominant polycystic kidney disease | University of Colorado, Denver | Completed | Missed primary |
| Phase 4 | NCT01052025 | Aug 2009 → Mar 2010 | prediabetes syndrome, type 2 diabetes mellitus | Srinakharinwirot University | Unknown | Met primary |
| Phase 4 | NCT01052597 | Jul 2009 → Feb 2010 | type 2 diabetes mellitus | Srinakharinwirot University | Unknown | No outcome recorded |
| Phase not applicable20 trials · 1 missed | ||||||
| — | NCT07785986 | Aug → Sep 2026 | — | University of Valladolid | Completed | No outcome recorded |
| — | NCT07436130 | Mar 2026 → Mar 2027 expected | infectious disease with sepsis | Hospital Civil de Guadalajara | Recruiting | No outcome recorded |
| — | NCT07523256 | Nov 2025 → Jan 2026 | schizophrenia | Rinvil Renaldi | Completed | No outcome recorded |
| — | NCT06478290 | Oct 2025 → Jul 2026 overdue | — | University of Manitoba | Not yet recruiting | No outcome recorded |
| — | NCT06932848 | Jun 2025 → Jun 2026 overdue | oral erosive lichen | Chulalongkorn University | Recruiting | No outcome recorded |
| — | NCT05947513 | Apr 2025 → Feb 2026 overdue | cervical cancer | Addis Ababa University | Recruiting | No outcome recorded |
| — | NCT06777303 | Jun 2024 → Aug 2025 overdue | periodontitis | Mansoura University | Active not recruiting | No outcome recorded |
| — | NCT04800107 | Jan 2021 → Dec 2025 | tinnitus | Henry Ford Health System | Withdrawn | No outcome recorded |
| — | NCT05667376 | Jan → May 2021 | periodontitis | Reham abdelfatah | Completed | No outcome recorded |
| — | NCT04315350 | Dec 2019 → Jun 2021 | NAFLD1 | University Hospital, Gentofte, Copenhagen | Terminated | No outcome recorded Stop: Enrollment |
| — | NCT04012424 | Aug 2019 → Aug 2020 | pulpitis | Cairo University | Completed | No outcome recorded |
| — | NCT03864783 | Mar 2019 → Dec 2020 | NAFLD1, abdominal obesity-metabolic syndrome, glucose intolerance | Steno Diabetes Center Copenhagen | Completed | No outcome recorded |
| — | NCT03598205 | Feb → Sep 2018 | diabetic macular edema | Fondazione G.B. Bietti, IRCCS | Completed | No outcome recorded |
| — | NCT03122613 | Jun 2017 → May 2020 | ulcerative colitis | Chinese University of Hong Kong | Terminated | No outcome recorded |
| — | NCT01968564 | Jun 2013 → Jun 2017 | vascular disorder | University of Colorado, Boulder | Unknown | No outcome recorded |
| — | NCT00927485 | Nov 2007 → Nov 2016 | classic familial adenomatous polyposis | University of Puerto Rico | Completed | No outcome recorded |
| — | NCT00181662 | Aug 2005 → Oct 2007 | — | Massachusetts General Hospital | Completed | No outcome recorded |
| — | NCT01514266 | Apr 2005 → May 2007 | chronic obstructive pulmonary disease | Baylor College of Medicine | Completed | No outcome recorded |
| — | NCT00113841 | Nov 2004 → Aug 2009 | plasma cell myeloma | M.D. Anderson Cancer Center | Completed | Missed primary |
| — | NCT00176618 | Apr 2004 → Jun 2007 | — | University of Medicine and Dentistry of New Jersey | Terminated | No outcome recorded |
| Comparator or background therapy26 trials | ||||||
| Phase 1 | NCT04007224 Comparator | Jan 2019 → Jun 2023 | autism spectrum disorder | Fundatia Bio-Forum | Completed | No outcome recorded |
| Phase 1 | NCT01330810 Comparator | Mar → Dec 2011 | — | University of North Carolina, Chapel Hill | Completed | No outcome recorded |
| Phase 1/2 | NCT05774704 Comparator | Aug 2023 → Dec 2026 expected | — | Texas Tech University Health Sciences Center | Recruiting | No outcome recorded |
| Phase 1/2 | NCT01048983 Comparator | — | non-small cell lung carcinoma | M.D. Anderson Cancer Center | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT06470061 Comparator | Jul 2024 → Jul 2027 expected | Alzheimer disease, cognitive impairment with or without cerebellar ataxia | Zaparackas and Knepper LTD | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT05062486 Comparator | Oct 2021 → Nov 2024 | age-related macular degeneration | Paul A Knepper, MD PhD | Completed | No outcome recorded |
| Phase 2 | NCT05045443 Comparator | Aug 2021 → Dec 2022 | childhood acute lymphoblastic leukemia | Ain Shams University | Completed | No outcome recorded |
| Phase 2 | NCT04713631 Comparator | Jan 2021 → Dec 2023 | Crohn disease | Sanjay Gandhi Postgraduate Institute of Medical Sciences | Unknown | No outcome recorded |
| Phase 2 | NCT04109742 Comparator | Dec 2019 → Apr 2020 | NAFLD1, metabolic dysfunction-associated steatohepatitis | Columbia University | Withdrawn | No outcome recorded Stop: Business |
| Phase 2 | NCT03072992 Comparator | Mar 2017 → Nov 2018 | breast cancer | National Center of Oncology, Armenia | Completed | No outcome recorded |
| Phase 2 | NCT03511261 Comparator | Jan 2014 → Dec 2018 | oral submucous fibrosis | H.K.E.S's S.Nijalingappa Institute of Dental Science and Research | Unknown | No outcome recorded |
| Phase 2 | NCT01269203 Comparator | Oct 2012 → Oct 2015 | plasma cell myeloma | M.D. Anderson Cancer Center | Withdrawn | No outcome recorded |
| Phase 2 | NCT01383161 Comparator | Mar 2012 → Apr 2017 | subjective cognitive decline | University of California, Los Angeles | Completed | No outcome recorded |
| Phase 2 | NCT01042938 Comparator | Jan 2008 → Sep 2010 | breast cancer | University of Rochester | Completed | No outcome recorded |
| Phase 3 | NCT06758739 Comparator | Apr → Sep 2025 overdue | oral submucous fibrosis | Services Institute of Medical Sciences, Pakistan | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT05613361 Comparator | Jan 2023 → Apr 2024 | acute kidney injury | October 6 University | Unknown | No outcome recorded |
| Phase 3 | NCT03769766 Comparator | Mar 2019 → Nov 2029 expected | prostate cancer | University of Texas Southwestern Medical Center | Recruiting | No outcome recorded |
| Phase 3 | NCT02369549 Comparator | Sep 2015 → Nov 2019 | chronic kidney disease | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Completed | No outcome recorded |
| Phase 3 | NCT02064673 Comparator | May 2014 → Jun 2028 expected | prostate cancer | yair lotan | Recruiting | No outcome recorded |
| Phase 3 | NCT01831193 Comparator | Feb 2013 → Apr 2014 | proteinuria | Instituto Nacional de Cardiologia Ignacio Chavez | Completed | No outcome recorded |
| Phase 3 | NCT00528151 Comparator | May 2005 → Dec 2007 | Leber hereditary optic neuropathy | Mahidol University | Completed | No outcome recorded |
| Phase 4 | NCT04044417 Comparator | Aug 2016 → May 2018 | periodontitis | Ain Shams University | Completed | No outcome recorded |
| Phase 4 | NCT02298985 Comparator | Jan 2015 → Jan 2017 | schizophrenia | Beersheva Mental Health Center | Completed | No outcome recorded |
| Phase 4 | NCT01750359 Comparator | Aug 2010 → May 2011 | major depressive disorder | Vladimir Lerner | Completed | No outcome recorded |
| — | NCT05982197 Comparator | Jan → Mar 2023 | head and neck cancer, mucositis | University of Baghdad | Completed | No outcome recorded |
| — | NCT03144882 Comparator | Feb 2015 → Feb 2016 | dialysis disequilibrium syndrome | Shahid Beheshti University of Medical Sciences | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2025-04-27 | Laboratorios Rubió | Results OTC Supplements: 2025’s Revolution in Preventive Health laboratoriosrubio.com ↗
A 2014 clinical trial in Clinical Interventions in Aging found curcumin supplementation as effective as ibuprofen for knee osteoarthritis pain relief, with fewer gastrointestinal side effects. |
| 2022-04-28 | Indena S.p.A | Results MERIVA® – Indena’s Curcumin Phytosome®: a natural and safe help for body detox indena.com ↗
New clinical evidences show that Meriva ® is an effective oxidative stress modulator, also in the support of kidney detoxing and filtering functions. |
| 2020-03-19 | Eye Pharma | Results Risultati di uno studio pilota sugli effetti positivi della Curcuma Fitosoma nella progressione della degenerazione maculare legata all’età eyepharma.com ↗ |
| 2017-07-24 | Eye Pharma | Results Anche l’Atletico Bilbao sceglie il Meriva®, la curcumina ad alta disponibilità eyepharma.com ↗
I soggetti del gruppo trattato con Meriva® hanno segnalato meno dolore agli arti inferiori rispetto ai soggetti del gruppo placebo, così come erano minori i casi di lesioni muscolari evidenziati dalla risonanza magnetica. |
All press releases naming this drug 5 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-04-27 | Laboratorios Rubió | OTC Supplements: 2025’s Revolution in Preventive Health laboratoriosrubio.com ↗ |
| 2022-04-28 | Indena S.p.A | MERIVA® – Indena’s Curcumin Phytosome®: a natural and safe help for body detox indena.com ↗ |
| 2020-03-19 | Eye Pharma | Risultati di uno studio pilota sugli effetti positivi della Curcuma Fitosoma nella progressione della degenerazione maculare legata all’età eyepharma.com ↗ |
| 2017-07-24 | Eye Pharma | Anche l’Atletico Bilbao sceglie il Meriva®, la curcumina ad alta disponibilità eyepharma.com ↗ |
| 2013-09-11 | Eisai Inc. | EISAI ANNOUNCES LAUNCH OF SELBELLE® UKON 27 PLUS GRANULE 30 mg OF HIGH-ABSORPTION CURCUMIN FOR APPROX. 27 TIMES THE ABSORPTION! eisai.com ↗ |
Evidence & citations 32 cited values
Every value below carries the sentence it was read from. 160 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | curcumin | “Upgraded curcumin capsules(CuminUP60®) is made from curcumin with a natural extraction content of 95% and excipients through physical process microprocessing, with a curcumin...” NCT04972045 ↗152“daily administration of oxytocin, 10 UI intrnasal, 5 UI bid, and if needed curcumin orally 250 mg bid, and/or lecithin 500 mg bid, and/or pironoquinolinquinone, 20 mg qd” NCT04007224 ↗ “CurcuVIVA™ is given in capsule forms. Unit strength of CurcuVIVA™ is equal to Turmeric Extract 25:1 348 mg (containing 80mg Longvida® Optimized Curcumin)” NCT02321293 ↗ “Oral curcumin formulation (DIABEC 2 tablets/die) in combination with Dexamethazone (0,7 mg) intravitral injection for diabetic macular edema treatment” NCT03598205 ↗ “Curcumin, an active ingredient of the Indian herb Rhizoma Curcuma Longa, has been extensively studied in the context of inflammatory diseases.” NCT01320436 ↗ “Each capsule is a bio-enhanced modification of curcumin (diferuloylmethane), which is a derivative of curcuma longa (rhizome extract)” NCT02683759 ↗ “Each capsule is a bio-enhanced modification of curcumin (diferuloylmethane), which is a derivative of curcuma longa (rhizome extract)” NCT02683733 ↗ “Curcumin is provided in soft gelatin capsules each capsule contains 1 g of curcumin and patient is asked to take 2 capsules daily” NCT05966441 ↗ “patients are treated with SRP in addition to curcumin loaded on chitosan nano-particles as an adjunct local drug delivery.” NCT06777303 ↗ “Curcumin extract 1000 mg/day administered orally as an adjuvant therapy in combination with risperidone for 8 weeks.” NCT07523256 ↗ “Curcumin is an extract of the tumeric root that has been shown to have anti-tumor properties in laboratory studies.” NCT01859858 ↗ |
| Known as | BCM-95 curcumin | “Each each 750 mg CuraMed® softgel supplies 500 mg of highly bioavailable BCM-95 curcumin.” NCT02978339 ↗ |
| Known as | BEC | “The aim of this study was to assess the efficacy and safety of a novel, hydrophilic, bioenhanced curcumin (BEC) as add-on therapy in inducing clinical and endoscopic remission...” PMID 32889959 ↗ Sep 2021 |
| Known as | C3-complex curcumin (diferuloylmethane) | “C3-complex curcumin (diferuloylmethane)” NCT01490996 ↗ |
| Known as | Calcumin | “Calcumin (Curcumin)” NCT00927485 ↗ |
| Known as | CUR | “Curcumin (Cur), an active ingredient of the Indian herb Rhizoma Curcuma Longa” NCT05596214 ↗1“Curcumin (CUR), 7-bis (4-hydroxy-3-methoxyphenyl)-1,6- heptadien-3, 5-dione” NCT06029023 ↗ |
| Known as | curcum | “other name : curcum, tumeric” NCT04012424 ↗ |
| Known as | Curcumin C3 Complex | “Curcumin (Curcumin C3 Complex prepared by Sabinsa Corporation), a constituent of the spice turmeric, is considered to be a low-toxicity, dietary-derived agent with...” NCT04266275 ↗1“Drug: Curcumin C3 Complex” NCT01042938 ↗ |
| Known as | Curcumin Forte | “Curcumin is provided as Curcumin Forte ® (Solgar Israel SupHerb).” NCT02298985 ↗ |
| Known as | Curcumin Gel | “Drug: Curcumin Gel” NCT06342830 ↗ |
| Known as | Curcuminoids | “Investigational Active Ingredients: Curcuminoids (syn: Curcumin, isolated from turmeric rhizome Curcuma longa, Zingiberaceae.” NCT03072992 ↗ |
| Known as | curenext | “curcuma longa oral gel (curenext)” NCT05982197 ↗ |
| Known as | DIABEC | “Oral curcumin formulation (DIABEC 2 tablets/die) in combination with Dexamethazone (0,7 mg) intravitral injection for diabetic macular edema treatment” NCT03598205 ↗ |
| Known as | diferulomethane | “For example, curcumin (diferulomethane), a low molecular weight molecule with antioxidant and anti-inflammatory activities that is derived from dietary spice” NCT01383161 ↗ |
| Known as | diferuloylmethane | “PURPOSE: Pancreatic cancer is almost always lethal, and the only U.S. Food and Drug Administration-approved therapies for it, gemcitabine and erlotinib, produce objective...” PMID 18628464 ↗ Jul 200810“Curcumin (diferuloylmethane), a yellow pigment that is obtained from the rhizomes of Curcuma longa Linn., is a major component of turmeric and is commonly used as a spice and...” PMID 7954412 ↗ Nov 1994 “Modulation of pathological angiogenesis by curcumin (diferuloylmethane), the active principle of turmeric, seems to be an important possibility meriting mechanistic investigations.” PMID 12359244 ↗ Oct 2002 “Curcumin (diferuloylmethane) is the chief component of the spice turmeric and is derived from the rhizome of the East Indian plant Curcuma longa.” NCT02645656 ↗ “Curcumin (diferuloylmethane), a constituent of Curcuma longa plant, which possess antioxidant, anti-inflammatory, and anti-microbial properties.” NCT04355416 ↗ “Curcumin (diferuloylmethane) is a natural compound derived from the rhizome of Curcuma Longa, an East Indian plant, commonly called turmeric.” NCT00295035 ↗ “Curcumin (diferuloylmethane) is a natural compound derived from the rhizome of Curcuma Longa, an East Indian plant, commonly called turmeric.” NCT00486460 ↗ “Curcumin is (diferuloylmethane), a yellow pigment in curry powder, exhibits anti-oxidant, anti-inflammatory, and pro-apoptotic activities.” PMID 25737939 ↗ Nov 2014 “Each capsule is a bio-enhanced modification of curcumin (diferuloylmethane), which is a derivative of curcuma longa (rhizome extract)” NCT02683759 ↗ “Each capsule is a bio-enhanced modification of curcumin (diferuloylmethane), which is a derivative of curcuma longa (rhizome extract)” NCT02683733 ↗ “Curcumin (diferuloylmethane) is a major constituent in the spice turmeric, which is used as a food worldwide.” NCT00219882 ↗ |
| Known as | Diferuloylmethane Derivative | “Curcumin (Diferuloylmethane Derivative) With or Without Bioperine in Patients With Multiple Myeloma” NCT00113841 ↗ |
| Known as | LipoCurc | “Agent: LipoCurc Premedication/Precautions: Dexamethasone 4mg IV, Diphenhydramine 25 mg IV - Dose: per treatment assignment Route: IV over approximately 3 hours Schedule:...” NCT05768919 ↗1“Liposomal Curcumin (LipoCurc)” NCT07456605 ↗ |
| Known as | Liposomal Curcumin | “Liposomal Curcumin (LipoCurc)” NCT07456605 ↗ |
| Known as | Longvida | “The investigational product consists of an oral, enhanced-bioavailability formulation of curcumin (Longvida®).” NCT07436130 ↗2“Curcumin (Longvida™) or matching placebo.” NCT00752154 ↗ “Dietary Supplement: Curcumin (Longvida™)” NCT06829186 ↗ |
| Known as | Longvida Curcumin (Verdure Sciences, Indianapolis) | “Longvida Curcumin (Verdure Sciences, Indianapolis)” NCT01811381 ↗ |
| Known as | Lonvida | “Patients will receive curcumin (Lonvida) 2000 mg PO once a day” NCT03223883 ↗ |
| Known as | Meriva | “Curcumin (Meriva) was safe, well-tolerated, and showed potential as a curcuminoid chemoprevention agent in H. pylori-negative patients with GPMC.” PMID 42077070 ↗ Jul 2026 |
| Known as | sinacurcumin | “In the simultaneous intervention group, patients will take daily curcumin tablets (sinacurcumin product) at a dose of 40 mg twice a day for three months (at the same time as...” NCT06595355 ↗ |
| Known as | THERACURMIN CR-011L | “Phase I Study of Surface-Controlled Water Soluble Curcumin (THERACURMIN CR-011L)” NCT01201694 ↗ |
| Known as | tumeric | “other name : curcum, tumeric” NCT04012424 ↗ |
| Known as | Turmeric | “Curcumin (Turmeric)” NCT06758739 ↗ |
| Known as | turmeric extract | “Curcumin (turmeric extract), over the counter supplement (1 capsule/three times a day).” NCT03845322 ↗ |
| Known as | Turmix | “the second group by oral administration of two Curcumin tablets (Turmix 300 mg) per day for 3 months each.” PMID 25737939 ↗ Nov 2014 |
| Action | Inhibit | “Curcumin is a potent inhibitor of the endoplasmic reticulum (ER) Ca2+ pump” NCT00219882 ↗ |
| Modality | Small molecule | “Curcumin is a polyphenolic molecule extracted from turmeric” NCT00164749 ↗ |
| Route | Oral | “you will receive curcumin by mouth every day” NCT00094445 ↗ |
| Target | IL8 | “Curcumin gel may have anti-inflammatory effect by reducing IL-8” NCT04355416 ↗ |